| Price Range 12mo avg: | $2M – $2.5M |
|---|---|
| $/sf 12mo avg: | $318.75 |
| CAP Rate 12mo avg: | 7.29% |
| NOI average: | $173,700 |
| Lease Terms: | 15yrs NNN |
| Building Size avg: | 7,500 SF |
| Lot Size avg: | 2.5+/- acres |
Fresenius is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home.
The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS)
Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.7 million individuals worldwide. Through its network of 3,361 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 286,312 patients around the globe. Fresenius Medical Care is also the world’s leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
| S&P Credit Rating: | BBB- |
|---|---|
| Moody’s Credit Rating: | Ba1 |
| Annual Revenue 2014: | $15.8B |
| Annual Revenue 2013: | $14.6B |
| Revenue Growth: | ↑ 8% from 2013 |
| Net Income | $1.05B |
| Units (Dec. 2014) | 3,361 |
| Average Units Volume: | $4.7M |
Yahoo! Finance: FMS News Latest Financial News for FMS
-
Why Chicago Bridge & Iron, Akorn, and Flotek Industries Slumped Today
on April 23, 2018 at 8:33 pm
Find out why these stocks led the market lower. […]
-
Jilted Akorn sues Fresenius over deal termination
on April 23, 2018 at 2:59 pm
U.S. generic drugmaker Akorn (AKRX.O) is taking former suitor Fresenius (FREG.DE) to court after the German healthcare group cancelled their $4.75 billion (3.4 billion pounds) takeover agreement. Akorn shares lost more than a third of their value on Monday, the day after Fresenius pulled out of a deal first announced last April. The German company cited evidence of misconduct in Akorn's reporting of drug development data to U.S. healthcare regulators. […]
-
Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations
on April 23, 2018 at 1:42 pm
dropped its planned $5 billion takeover of the generic drugmaker after a probe into possible data breaches by the U.S. Food & Drug Administration. Fresenius said it found "material" breaches of FDA1 data integrity rules as part of its own investigation into allegations levelled against the Lake Forest, Ill.-based Akorn earlier this year and offered to delay its proposed takeover if the group could supply information that would allow Fresenius to reconsider. The Germany company said Akorn declined that offer. […]
-
Fresenius shares gain after it ditches Akorn takeover
on April 23, 2018 at 10:25 am
Shares in healthcare group Fresenius jumped as much as 3.9 percent after it pulled out of the $4.75 billion acquisition of Akorn, with analysts saying it was extricating itself from taking on an underperforming business. Germany's Fresenius on Sunday cited evidence of misconduct in the target's reporting of drug development data to U.S. healthcare regulators, but analysts pointed to investor relief because Akorn's business had deteriorated. "Investors will likely be pleased that the merger agreement has been terminated, given the substantial decline in Akorn’s operating performance since the agreement was signed last April," said Berenberg analyst Tom Jones. […]
-
Germany's Fresenius, US-based Akorn at odds over merger deal
on April 23, 2018 at 10:02 am
BERLIN (AP) — Germany's Fresenius and U.S.-based pharmaceutical manufacturer Akorn Inc. are at odds over the German company's decision to terminate a more than $4.3 billion takeover agreement, citing alleged breaches of data integrity requirements. […]
NYSE: FMS
